BioCentury | Nov 7, 2020
Translation in Brief

Neoleukin’s ACE2 decoy protects hamsters from SARS-CoV-2; plus a circular RNA linked to diabetes and more

...BioCentury’s roundup of translational news By Danielle Golovin, Staff Writer Neoleukin’s ACE2 decoy for COVIDNeoleukin Therapeutics...
...candidate, protected hamsters from lethal SARS-CoV-2 challenge. The company is determining whether to advance the bivalent ACE2...
...influenza A and B infection.TARGETSACE2Angiotensin-converting enzyme 2 Danielle Golovin Relenza, zanamivir (GG167) Neoleukin Therapeutics Inc. University of Lausanne Purdue University Vaxart Inc. Angiotensin-converting enzyme 2 (ACE2) SARS-CoV-2...
BioCentury | Nov 6, 2020
Targets & Mechanisms

Data Byte: newly identified host factors that regulate ACE2 expression

...recent publications highlighting host factors that modulate ACE2...
...point to possible new targets for COVID-19 therapies. ACE2...
...immediately downstream of the ACE2 transcription start site and reduced ACE2...
BioCentury | Oct 27, 2020
Distillery Therapeutics

UCSF team develops trivalent binder of SARS-CoV-2 spike for COVID-19

...Inc. (NASDAQ:SNSS) founder Jim Wells has developed a trivalent immunoglobulin variable heavy domain-based inhibitor of the ACE2-SARS-CoV-2...
...to identify compounds capable of binding multiple epitopes on SARS-CoV-2 S, including those at the ACE2...
...entry into monkey kidney epithelial cells with an IC50 of 3.98 nM.Other therapies targeting the ACE2-SARS-CoV-2...
BioCentury | Oct 17, 2020
Translation in Brief

SARS-CoV-2 infects brain choroid plexus, compromises CSF-blood barrier; plus Passage’s GM1 gangliosidosis gene therapy, a new COVID-19 reporter and more

...Cell Stem Cell, which also showed higher ACE2...
...Medicale (INSERM) QIMR Berghofer Medical Research Institute University of Oslo Angiotensin-converting enzyme 2 (ACE2) CD226...
BioCentury | Oct 3, 2020
Product Development

Oral drugs and treatments for life-threatening diseases stand out among new product launches

Despite the challenge of introducing a drug to the market during the COVID-19 pandemic, sales of nearly all new product launches increased in 2Q20 versus 1Q, with drugs to treat life-threatening conditions and oral products...
BioCentury | Oct 2, 2020
Finance

Sophia aims to parlay expertise of new backers aMoon, Hitachi to grow biopharma business

Genomics data company Sophia looked increasingly to healthcare investors when putting together the syndicate for its new $110 million series F round, which will go toward building the biopharma side of...
BioCentury | Sep 11, 2020
Product Development

Yale’s Akiko Iwasaki shows SARS-CoV-2 invades neurons

...levels of ACE2 mRNA, the virus’ host cell receptor, the team demonstrated that the cells express ACE2...
...safety event.AZ and Serum Institute did not respond to BioCentury in time for comment.TARGETSACE2Angiotensin-converting enzyme 2 Sandi...
BioCentury | Sep 10, 2020
Product Development

BioNTech, Pfizer complete exploratory talks with the European Commission for 200M COVID-19 vaccine doses

...spike protein and its host cell receptor ACE2...
...that binds ACE2, or the portion of ACE2...
...to support a Phase II/III trial.TARGETSACE2Angiotensin-converting enzyme 2 Sandi...
BioCentury | Aug 29, 2020
Product Development

COVID-19 Quick Takes: FDA expands remdesivir EUA; plus Warp Speed, Abbott, Moderna-Japan, CanSino-Canada, BeiGene-Singlomics, Sinovac, UNC, Daiichi, Laurent

...mice infected with the mouse-adapted SARS-CoV-2 strain had more clinically relevant COVID-19 phenotypes than human ACE2-expressing...
BioCentury | Aug 26, 2020
Finance

Partnerships paved the way to a Tokyo IPO for Modalis

Modalis paved its way to a public listing on the Tokyo Stock Exchange’s Mothers through a series of early pharma partnerships leveraging its CRISPR-based gene modulation platform. Shares of Modalis Therapeutics...
Items per page:
1 - 10 of 726